1-4 of 4
Esther Rose
Close
Sort by
Journal Articles

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

David P. Steensma, Uwe Platzbecker, Koen Van Eygen, Azra Raza, MD, Valeria Santini, Ulrich Germing, MD, Patricia Font, MD, Irina Samarina, MD, Maria Díez-Campelo, Sylvain Thepot, MD, Edo Vellenga, Mrinal M. Patnaik, MDMBBS, Jun Ho Jang, MD PhD, Jacqueline Bussolari, PhD, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Pierre Fenaux
Journal: Blood
Blood (2018) 132 (Supplement 1): 463.
https://doi.org/10.1182/blood-2018-99-114877
Published: 2018
Journal Articles

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, MD, Bruno Martino, MD, Dietger Niederwieser, MD, Andreas Reiter, MD, Bart L Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Jacqueline Bussolari, PhD, Eugene Zhu, PhD, Fei Huang, PhD, Esther Rose, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Faye M. Feller, MD, Jean-Jacques Kiladjian, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 685.
https://doi.org/10.1182/blood-2018-99-115163
Published: 2018
Journal Articles

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

Pierre Fenaux, MD PhD, Azra Raza, MD, Edo Vellenga, MD, Uwe Platzbecker, MD, Valeria Santini, MD, Irina Samarina, MD, Koen Van Eygen, MD, Maria Díez-Campelo, MD PhD, Mrinal M. Patnaik, MDMBBS, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Aleksandra Rizo, MD PhD, David P. Steensma, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4256.
https://doi.org/10.1182/blood.V130.Suppl_1.4256.4256
Published: 2017
Journal Articles

Phase 1 study of polyethylene glycol formulation of interferon α-2B (Schering 54031) in Philadelphia chromosome–positive chronic myelogenous leukemia

Clinical Trials & Observations
Moshe Talpaz, Susan O'Brien, Esther Rose, Samir Gupta, Jianqin Shan, Jorge Cortes, Francis J. Giles, Stefan Faderl, Hagop M. Kantarjian
Journal: Blood
Blood (2001) 98 (6): 1708–1713.
https://doi.org/10.1182/blood.V98.6.1708
Published: 2001